Abstract: Objective : To study the clinical effect of Jinlong capsule on primary hepatic carcinoma (PHC). Method : A total of 224 cases with PHC, who failed to be treated by operation, were classified randomly into two groups: combination therapy group (treat group, 116 cases) and chemotherapy and embolization group (control group, 108 cases). The effect, survival rate and life quality was respectively evaluated at 6 months, 1, 2 and 3 years after treatment. Results : The survival rate and life quality of treatment group were better than control group significantly (P<0.05) at 1, 2 and 3 years after treatment. Conclusions : Jinlong capsule can significantly improve the survival time and life quality of patients with PHC. it is an effective drug for the treatment of PHC.